157 related articles for article (PubMed ID: 37995426)
1. Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy.
Abed A; Beasley AB; Reid AL; Law N; Calapre L; Millward M; Lo J; Gray ES
ESMO Open; 2023 Dec; 8(6):102066. PubMed ID: 37995426
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
4. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.
Ji S; Li J; Chang L; Zhao C; Jia R; Tan Z; Liu R; Zhang Y; Li Y; Yin G; Guan Y; Xia X; Yi X; Xu J
Clin Transl Oncol; 2021 Aug; 23(8):1646-1656. PubMed ID: 33583004
[TBL] [Abstract][Full Text] [Related]
7. Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.
Kurokawa K; Mitsuishi Y; Shimada N; Kawakami Y; Miura K; Miyawaki T; Asao T; Ko R; Shukuya T; Shibayama R; Nojiri S; Takahashi K
BMC Cancer; 2022 Oct; 22(1):1047. PubMed ID: 36203123
[TBL] [Abstract][Full Text] [Related]
8. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.
Borghaei H; Langer CJ; Gadgeel S; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Saraf S; Keller SM; Gandhi L
J Thorac Oncol; 2019 Jan; 14(1):124-129. PubMed ID: 30138764
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anti-PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Wang L; Yang Y; Yu J; Zhang S; Li X; Wu X; Nie X; Liu W; Zhang P; Li Y; Li A; Ai B
Thorac Cancer; 2022 Feb; 13(3):322-337. PubMed ID: 34907661
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics.
Liu W; Huo G; Chen P
BMC Cancer; 2023 May; 23(1):458. PubMed ID: 37202730
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
12. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Di Noia V; D'Argento E; Pilotto S; Vita E; Ferrara MG; Damiano P; Ribelli M; Cannella A; Virtuoso A; Fattorossi A; Ceresoli GL; Milella M; Beretta GD; Tortora G; Bria E
Cancer Immunol Immunother; 2021 Jun; 70(6):1583-1592. PubMed ID: 33231726
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
15. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis.
Kim R; Keam B; Hahn S; Ock CY; Kim M; Kim TM; Kim DW; Heo DS
Clin Lung Cancer; 2019 Sep; 20(5):331-338.e4. PubMed ID: 31164319
[TBL] [Abstract][Full Text] [Related]
16. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
17. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Ramalingam SS; Thara E; Awad MM; Dowlati A; Haque B; Stinchcombe TE; Dy GK; Spigel DR; Lu S; Iyer Singh N; Tang Y; Teslenko I; Iannotti N
Cancer; 2022 Jan; 128(1):65-74. PubMed ID: 34478166
[TBL] [Abstract][Full Text] [Related]
18. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Salous T; Shukla NA; Althouse SK; Perkins SM; Furqan M; Leal T; Traynor AM; Feldman LE; Hanna NH; Durm GA
Cancer; 2023 Jan; 129(2):264-271. PubMed ID: 36420773
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]